Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Scholar Rock Holding Corporation - Common Stock (NQ:SRRK)

36.99 +2.75 (+8.03%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 9, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,689,314
Open 34.70
Bid (Size) 37.00 (1)
Ask (Size) 37.66 (1)
Prev. Close 34.24
Today's Range 34.52 - 37.84
52wk Range 6.760 - 46.98
Shares Outstanding 94,873,407
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Scholar Rock to Present Comprehensive Update at 2025 Annual Cure SMA Research and Clinical Care Meeting, Including Positive Results from Pivotal Phase 3 SAPPHIRE Trial
From Scholar Rock
Via Business Wire
Scholar Rock Stock Soars After Investigational Drug Helps Preserve Lean Mass: Retail Flags Lack Of Incremental Weight Loss
Apitegromab therapy with Tirzepatide preserved an additional 4.2 pounds of lean mass compared to Tirzepatide alone in the study, the company said. 
Via Stocktwits
Topics Death

Performance

YTD
-16.2%
-16.2%
1 Month
+8.6%
+8.6%
3 Month
+36.7%
+36.7%
6 Month
-9.4%
-9.4%
1 Year
+369.4%
+369.4%

More News

Read More
Why Scholar Rock Shares Are Soaring Today
Via The Motley Fool
Topics Stocks
Scholar Rock's Atrophy Drug When Combined With Eli Lilly's Zepbound Shows Around 55% Better Muscle Preservation In Weight Loss Study
Via Benzinga
A Look Ahead: Scholar Rock Holding's Earnings Forecast
Via Benzinga
Which stocks are gapping on Wednesday?
Via Chartmill
Wondering what's happening in today's pre-market session?
Via Chartmill
Scholar Rock Reports Positive Phase 2 EMBRAZE Trial Results Demonstrating Statistically Significant Preservation of Lean Mass with Apitegromab During Tirzepatide-Induced Weight Loss
From Scholar Rock
Via Business Wire
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Scholar Rock
Via Business Wire
Jefferies Names Akero Therapeutics, Scholar Rock As Biotech Companies With Takeover Potential, But Retail Isn’t Pleased
Via Stocktwits
Greif Posts Upbeat Earnings, Joins Planet Labs PBC, IperionX, Owens & Minor And Other Big Stocks Moving Higher On Thursday
Via Benzinga
Scholar Rock to Participate in the 46th Annual Goldman Sachs Global Healthcare Conference
From Scholar Rock
Via Business Wire
Scholar Rock Appoints Rebecca McLeod Chief Brand Officer and U.S. General Manager
From Scholar Rock
Via Business Wire
Scholar Rock to Present at the Jefferies Global Healthcare Conference
From Scholar Rock
Via Business Wire
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Scholar Rock
Via Business Wire
Scholar Rock Reports First Quarter 2025 Financial Results and Highlights Business Progress
From Scholar Rock
Via Business Wire
Scholar Rock to Host Conference Call to Discuss First Quarter 2025 Financial Results and Provide Business Update on May 14, 2025
From Scholar Rock
Via Business Wire
Earnings Scheduled For May 14, 2025
Via Benzinga
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Scholar Rock
Via Business Wire
Why Scholar Rock Stock Took a Knock on Monday
Via The Motley Fool
Scholar Rock Appoints David L. Hallal as Chief Executive Officer; Also Announces Addition of Three Key Leaders to Scale for Next Phase of Growth
From Scholar Rock
Via Business Wire
Why Scholar Rock Holding Stock Topped the Market Today
Via The Motley Fool
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Scholar Rock
Via Business Wire
FDA Grants Priority Review for Biologics License Application (BLA) and EMA Accepts Marketing Authorisation Application (MAA) for Apitegromab as a Treatment for Spinal Muscular Atrophy
From Scholar Rock
Via Business Wire
Scholar Rock Stock Jumps On Additional Data From Pivotal Trial Of Muscular Dystrophy Treatment
Via Benzinga

Frequently Asked Questions

Is Scholar Rock Holding Corporation - Common Stock publicly traded?
Yes, Scholar Rock Holding Corporation - Common Stock is publicly traded.
What exchange does Scholar Rock Holding Corporation - Common Stock trade on?
Scholar Rock Holding Corporation - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Scholar Rock Holding Corporation - Common Stock?
The ticker symbol for Scholar Rock Holding Corporation - Common Stock is SRRK on the Nasdaq Stock Market
What is the current price of Scholar Rock Holding Corporation - Common Stock?
The current price of Scholar Rock Holding Corporation - Common Stock is 36.99
When was Scholar Rock Holding Corporation - Common Stock last traded?
The last trade of Scholar Rock Holding Corporation - Common Stock was at 07/09/25 04:00 PM ET
What is the market capitalization of Scholar Rock Holding Corporation - Common Stock?
The market capitalization of Scholar Rock Holding Corporation - Common Stock is 3.51B
How many shares of Scholar Rock Holding Corporation - Common Stock are outstanding?
Scholar Rock Holding Corporation - Common Stock has 4B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.